Health and Healthcare
Why Bristol-Myers Failure Is a Huge Win for Merck
Published:
Last Updated:
Shares of Bristol-Myers Squibb Co. (NYSE: BMY) took a nosedive in Friday’s session following an update in its late-stage Checkmate trial. Unfortunately the results did not reach the primary endpoint, and shareholders are consequently suffering. However, Bristol-Myer’s failure was a big win for Merck & Co. (NYSE: MRK) as shares climbed to close out the week.
Early on Friday, Bristol-Myers announced that CheckMate -026, a trial investigating the use of Opdivo (nivolumab) as monotherapy, did not meet its primary endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC).
The company will complete a full evaluation of the CheckMate -026 data and work with investigators on the future presentation of the results.
Overall, this is a huge blow to Bristol-Myers, while it is especially good for Merck, which has a competing drug that recently succeeded in its trial. Merck’s drug Keytruda also recently won the approval of the European Commission for patients with locally advanced or metastatic NSCLC.
Giovanni Caforio, M.D., CEO of Bristol-Myers, commented:
Opdivo has become a foundational treatment that is transforming cancer care across multiple tumor types. While we are disappointed CheckMate -026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase 3 CheckMate -227 study exploring the potential of the combination of Opdivo plus Yervoy for PD-L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD-L1 negative patients.
Shares of Bristol-Myers were last seen down 17% at $62.42, with a consensus analyst price target of $77.50 and a 52-week trading range of $51.82 to $77.12.
Merck traded up more than 7% at $62.10. The consensus price target is $62.15, and the 52-week range is $45.69 to $62.61.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
